A new study has found that individuals that have previously contracted COVID-19 show a more potent antibody response than those who were solely vaccinated for the respiratory virus.

As epidemiologists try to stay ahead of the spread of new coronavirus COVID-19, vaccine developers, like Sanofi and Johnson & Johnson, are focusing on the "spike" proteins that festoon viral surfaces. Following clues in genomes is critical to disrupting the tango of infectivity as viruses meet and merge with our cells.